Max Robotics — Global Service Robot Directory + US Certification

About

Kristy Robledo is a leading clinical trialist and biostatistician whose work has fundamentally reshaped surgical practice in gynecologic oncology. Her most impactful contribution stems from the landmark LACC trial, published in the *New England Journal of Medicine* (2018, over 1,850 citations). As a key biostatistician on this practice-changing study, Robledo helped demonstrate that minimally invasive radical hysterectomy was associated with significantly worse survival outcomes compared to open surgery for early-stage cervical cancer. This finding directly reversed a decade-long trend toward laparoscopic and robotic approaches, altering global treatment guidelines and sparking intense debate about surgical innovation and patient safety. Beyond this seminal work, Robledo leads the statistical design for the ANZGOG ENDO-3 trial (2021), a phase III study investigating sentinel node biopsy versus no retroperitoneal node dissection in early-stage endometrial cancer. Her expertise lies in designing pragmatic, high-impact randomized controlled trials that address critical uncertainties in cancer surgery. With a career dedicated to rigorous methodology and evidence-based change, Robledo exemplifies how biostatistics can drive real-world clinical transformation, saving lives by challenging established surgical dogma.